冯美萍 邓晓静 吴旭琴

    [摘要] 目的 观察屈螺酮炔雌醇片治疗子宫腺肌病术后的临床疗效及安全性。方法 选取2019年2月至2021年2月兰溪市人民医院收治的行子宫腺肌病保守术治疗后患者109例，采用随机数字表法将其分为对照组(n=55)及试验组(n=54)。两组患者均于月经期后3～7d于宫内放置左炔诺孕酮宫内缓释系统进行常规治疗，试验组患者在常规治疗基础上予屈螺酮炔雌醇片。比较两组患者治疗前及治疗3个月、6个月、12个月时的痛经程度，月经量，糖类抗原125(carbohydrate antigen 125，CA125)水平，1年内的再复发风险及不良反应发生率。结果 两组患者治疗3个月、6个月、12个月时的痛经程度、月经量、CA125水平均较治疗前下降，且试验组患者明显轻于对照组，差异有统计学意义(P0.05)。结论 屈螺酮炔雌醇片可有效减少子宫腺肌病术后患者的月经量，减轻痛经程度，有效预防子宫腺肌病再复发，不良反应较少。

    [關键词] 屈螺酮炔雌醇片；子宫腺肌病；术后；复发风险

    [中图分类号] R711? ? ? [文献标识码] A? ? ? [DOI] 10.3969/j.issn.1673-9701.2023.02.027

    [Abstract] Objective To observe the clinical efficacy and safety of drospirenone and ethinylestradiol in the treatment of adenomyosis after operation. Methods A total of 109 patients admitted to Lanxi People's Hospital after conservative treatment for adenomyosis from February 2019 to February 2021 were selected and divided into the control group (n=55) and the test group (n=54) using the random number table method. Patients in both groups received routine treatment with levonorgestrel intrauterine sustained release system 3-7 days after menstruation ......